QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Healthpeak Properties, Inc. (DOC)

Real Estate

No action
Fundamental
3
Sentiment
2
Technical
4

Do Nothing: qualitativeScore is 2, below the required floor of 3, and the SHADOW_FST9 paper branch is not enabled (shadow flag false), so no bullish entry is permitted even though the chart is constructive (price above every key moving average with a fresh MACD positive cross, RSI 65.2); fundamentalScore 3 and all technical gates passed.

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

Healthpeak Properties, Inc. is a real estate investment trust (REIT) focused on acquiring, managing, and developing properties for medical research and healthcare services. It is part of the S&P 500 index.

Fundamental

fair
Fundamental3
Mixed fundamentals

Healthpeak shows stable cash flow but faces challenges with flat funds from operations and a contracting lab segment.

Mixed but not distressed: an investment-grade healthcare REIT with $3.06B of trailing revenue, $976M of nine-month operating cash flow, a 5.9% dividend yield covered about 69% by FFO, roughly 5x net leverage and $3.8B of liquidity — offset by flat-to-declining FFO as adjusted per share ($1.76-$1.78 guided for 2026 versus about $1.79 in 2025), a contracting lab segment (occupancy 85.9% from 93.4%), GAAP earnings flattered by roughly $199M of one-time gains, and the added complexity of a consolidated 69%-owned Janus Living. At about 11.6x price-to-FFO with a levered DCF value of $23.70 (about 14.9% upside) against a $22 analyst target, the shares are mildly attractive but not compelling.

Sentiment

weak
Sentiment2
Absent catalysts

Sentiment is neutral with no significant catalysts or retail interest driving the stock.

Dominant near-term signal is the 2026-11-02 Q3 2026 print and third FY2026 FFO guidance raise (announced; FFO as adjusted $0.44 vs $0.43 FactSet), received ambiguously — GAAP EPS missed by $0.03, FFO per share fell year over year, the stock shrugged the print off, and Cantor Fitzgerald cut its target to $21 from $23 on 2026-11-04 (announced sell_side catalyst, bearish) — against a 14-day media aggregate of polarity_score approximately +0.21 and a flat delta versus a mildly constructive baseline discovery layer (item-level read, low-to-moderate confidence, because the baseline aggregate itself was unmeasured). Red-Flag Screen clean — no severe or moderate flag fired and no cap applies — but with no forward-dated catalyst inside 30 days and no market-rewarded bullish leg, the setup is forming-without-a-driver rather than genuinely mixed.

Technical

good
Technical4
Constructive chart

The stock's technical indicators are positive, with price above key moving averages and a fresh MACD positive cross.

Trend and momentum both read bullish: the close of 20.62 sits above SMA20 19.25, SMA50 19.74, SMA200 19.20, EMA9 19.86, EMA21 19.54 and the daily VWAP of 20.60, while MACD has crossed positive (line 0.17 above signal -0.06, histogram +0.23 and expanding for five sessions) and RSI14 is 65.2 with room to 70; dollar volume near $122M/day removes any execution concern. That earns a 4 for chart quality. The offsets are ADX14 easing to 24.74 from 25.5 and immediate overhead supply at 20.81 then 20.88-20.96. The trade itself is blocked upstream: qualitativeScore 2 is below the required floor of 3 and the SHADOW_FST9 paper branch is not enabled (shadow flag false), so no bullish action may be emitted regardless of how good the chart looks.

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.